|
News Feeds |
|
Crohn's News From Medical News Today
|
Latest Crohn's News From Medical News Today.
|
-
Discovery Could Improve Understanding Of Ulcerative Colitis, Lead To New Therapies
An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis. The findings, which appear as an advance online publication of the journal Nature Genetics, bring researchers closer to understanding the biological pathways involved in the disease and may lead to the development of new treatments that specifically target them.
-
GeneThera Will Test Milk And Dairy Products Due To Evidence Linking Johne's Disease To IBS And Crohn's Disease
GeneThera, Inc. (PINKSHEETS: GTHR) announced it will begin testing of raw and processed milk and dairy products using its Real Time PCR test for Johne's disease through its Wheat Ridge, CO laboratory.
-
Vital Clues About Cause Of Bowel Disease
Scientists have uncovered vital clues about how to treat serious bowel disorders by studying the behaviour of cells in the colon. Researchers at the University of Edinburgh believe a chemical messenger that is essential for developing a baby's gut in the womb could hold the key to new treatments for inflammatory bowel disease (IBD), a condition which affects 1 in 250 people in the UK.
-
New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease
Data presented this week by UCB at Advances in Inflammatory Bowel Diseases 2008, the Crohn's & Colitis Foundation's Clinical & Research Conference, demonstrated more than half (53.6%) of those moderate to severe Crohn's disease patients who had open fistulas at baseline had closure of fistulas by Week 26 following short-term induction therapy with CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNFa (Tumor Necrosis Factor alpha).
-
Musculoskeletal Center Wins $2.2 Million For Drug Safety
The University of Alabama at Birmingham (UAB) Center for Education and Research on Therapeutics (CERTs) has won a $2.2 million federal grant to study the risks and benefits of a newer class of medicines called biologics. These are genetically engineered therapies that target the immune system of patients who have rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.
|
News Feeds 
